Stockscreener 앱 받기
7.68
10.82%
0.75
시간 외 거래:
7.51
-0.17
-2.21%
전일 마감가:
$6.93
열려 있는:
$6.87
하루 거래량:
1.12M
Relative Volume:
3.95
시가총액:
$320.12M
수익:
$31.37M
순이익/손실:
$-53.77M
주가수익비율:
-5.3963
EPS:
-1.4232
순현금흐름:
$-49.02M
1주 성능:
-45.06%
1개월 성능:
-57.26%
6개월 성능:
-67.88%
1년 성능:
-28.62%
1일 변동 폭
$6.43
$7.79
1주일 범위
$5.81
$14.27
52주 변동 폭
$5.81
$27.72
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
SLN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SLN | 7.68 | 320.12M | 31.37M | -53.77M | -49.02M | -1.4232 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Silence Therapeutics Plc Adr 주식(SLN)의 최신 뉴스
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - Yahoo Finance
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study - Yahoo Finance
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
Silence Therapeutics weakness after AHA updates ‘overdone,’ says BMO Capital - TipRanks
SILENCE THERAPEUTICS PLC SPONSORED ADR trading resumes - TipRanks
Top 3 Health Care Stocks You'll Regret Missing In Q4 - Benzinga
Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty - Yahoo Finance
Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine By Investing.com - Investing.com South Africa
Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine - Investing.com
Biogen's Lupus Candidate Meets Key Goals in Phase III Study - Yahoo Finance
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease - Yahoo Finance
It makes sense and dollars to buy Silence Therapeutics Plc ADR (SLN) stock - SETE News
Silence Therapeutics Plc ADR (SLN) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
What Did We Find About Insider Trading At Silence Therapeutics Plc ADR (NASDAQ: SLN)? - Stocks Register
Silence Therapeutics shares start at Buy from Jefferies, reflecting strong clinical data - Investing.com UK
H.C. Wainwright reiterates Buy on Silence Therapeutics stock amid strong trial results By Investing.com - Investing.com South Africa
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years - Yahoo Finance
How did Silence Therapeutics Plc ADR (SLN) fare last session? - US Post News
Ratio Revelations: Silence Therapeutics Plc ADR (SLN)’s Financial Metrics in the Spotlight - The Dwinnex
Silence Therapeutics Plc ADR (SLN) deserves closer scrutiny - US Post News
Market Insight: Silence Therapeutics Plc ADR (SLN)’s Notable Drop, Closing at 16.70 - The Dwinnex
It would be worthwhile to take a closer look at Silence Therapeutics Plc ADR (SLN) - US Post News
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last? - Yahoo Finance
Silence Therapeutics Plc ADR (SLN) deserves closer scrutiny – US Post News - US Post News
Silence Therapeutics stock holds Buy rating on positive trial results By Investing.com - Investing.com India
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics - Yahoo Lifestyle UK
Hardman & Co Insight: Survival of the UK life sciences sector - Research Tree
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Altria maintains stock target, Buy rating on FDA move By Investing.com - Investing.com UK
Zerlasiran shows promise in phase 2 study for cardiovascular risk By Investing.com - Investing.com
Is Silence Therapeutics Plc ADR (SLN) a good investment opportunity? – US Post News - US Post News
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates - Yahoo Finance
Trading Day Triumph: Silence Therapeutics Plc ADR (SLN) Ends at 21.54, a -2.49 Surge/Plunge – DWinneX - The Dwinnex
European Equities Traded in the US as American Depositary Receipts Start Week Off Lower Monday - MSN
Kirby Corp CEO sells shares worth over $360k By Investing.com - Investing.com
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains? - Yahoo Finance
BMO maintains $67 stock target on Silence Therapeutics stock By Investing.com - Investing.com UK
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains? - Yahoo Finance
All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy - Yahoo Finance UK
Does Silence Therapeutics PLC Sponsored ADR (SLN) Have the Potential to Rally 187.05% as Wall Street Analysts Expect? - Yahoo Finance
Wall Street Analysts Predict a 361.54% Upside in Silence Therapeutics PLC Sponsored ADR (SLN): Here's What You ... - Yahoo Finance UK
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains? - Yahoo Canada Finance
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues - Benzinga
The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO - Benzinga
The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping - Yahoo Finance
Silence Therapeutics Plc Adr (SLN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.55%
자본화:
|
볼륨(24시간):